Table 1_Characteristics, accessibility and regional equity evaluation of pediatric medicin

108 pediatric medicines were identified in China's National Reimbursement Drug List from 2017 to 2024. The dataset, authored by Xinyue Yuan and last updated in May 2026, evaluates their availability, affordability, and regional equity using metrics like Drug Availability Rate and Gini coefficients.

Use Cases

• Analyzing trends in pediatric medicine inclusion and negotiation delays based on the 4.40-year average market-to-listing delay.
• Evaluating regional equity in drug access based on calculated Gini coefficients below 0.4.
• Comparing affordability of Child-Specific Medicines versus Co-use Medicines based on Defined Daily Dose cost metrics.
• Assessing the impact of reimbursement on medicine affordability based on the increase from 78.70% to 96.30% affordable medicines.

Strengths

• Contains analysis of 108 distinct pediatric medicines with classifications for Co-use and Child-Specific types.
• Includes specific calculated metrics such as a 7.89% Drug Availability Rate in tertiary institutions and a Gini coefficient below 0.4.
• Covers a defined 7-year policy period from 2017 to 2024.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 62.1 KB file size suggests the dataset is likely a summary document rather than a raw data table.

Provenance

Source

figshare

Collection Method

Descriptive statistical analysis of medicines listed through China's National Drug Price Negotiation.

Time Range

2017–2024

Freshness

Last updated 2026-05-04 05:30:33; freshness should be verified.

Geography

China